The company's lead therapy is getting close to the finish line of FDA approval.
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -9.86% and 71.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could...
Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...
Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...